Annual report
4361.TEDINET S100XLSD
Period2024-12-01 → 2025-11-30
Filed2026-02-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.8bn | 2024-12-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥8.9bn | 2023-12-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥8.6bn | 2022-12-01 → 2023-11-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.4bn | 2021-12-01 → 2022-11-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2020-12-01 → 2021-11-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥427m | 2024-12-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥378m | 2023-12-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥405m | 2024-12-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥390m | 2023-12-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥345m | 2022-12-01 → 2023-11-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥303m | 2021-12-01 → 2022-11-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥386m | 2020-12-01 → 2021-11-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥404m | 2024-12-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥433m | 2023-12-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥256m | 2022-12-01 → 2023-11-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥219m | 2021-12-01 → 2022-11-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥281m | 2020-12-01 → 2021-11-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥298m | 2024-12-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | ¥336m | 2023-12-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥8.9bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥8.5bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥8.3bn | at 2023-11-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.3bn | at 2022-11-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥7.9bn | at 2021-11-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Cons. | Liabilities |
| Net assets / equity | ¥3.1bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥2.6bn | at 2023-11-30v | Cons. | Net assets |
| Net assets / equity | ¥2.4bn | at 2022-11-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.3bn | at 2021-11-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥745m | at 2024-11-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥745m | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2023-11-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥911m | at 2022-11-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.3bn | at 2021-11-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥830m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥143m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥470m | 2022-12-01 → 2023-11-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥21m | 2021-12-01 → 2022-11-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥785m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥739m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥305m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥370m | 2022-12-01 → 2023-11-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥243m | 2021-12-01 → 2022-11-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥246m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥360m | 2024-12-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥139m | 2023-12-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥21m | 2022-12-01 → 2023-11-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥162m | 2021-12-01 → 2022-11-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥119m | 2020-12-01 → 2021-11-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥245.11 | 2024-12-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.22 | 2023-12-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.88 | 2022-12-01 → 2023-11-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.75 | 2021-12-01 → 2022-11-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥230.99 | 2020-12-01 → 2021-11-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,574.02 | at 2025-11-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,367.69 | at 2024-11-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,167.14 | at 2023-11-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,980.62 | at 2022-11-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,850.07 | at 2021-11-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 35.3% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.8% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2023-11-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 29.0% | at 2022-11-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.5% | at 2021-11-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.9% | 2024-12-01 → 2025-11-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2023-12-01 → 2024-11-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2022-12-01 → 2023-11-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2021-12-01 → 2022-11-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-12-01 → 2021-11-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 160 | at 2025-11-30 | Cons. | Number of employees |
| Employees | 171 | at 2024-11-30 | Cons. | Number of employees |
| Employees | 166 | at 2023-11-30v | Cons. | Number of employees |
| Employees | 171 | at 2022-11-30v | Cons. | Number of employees |
| Employees | 165 | at 2021-11-30d | Cons. | Number of employees |
| Revenue | ¥8.6bn | 2024-12-01 → 2025-11-30 | Standalone | Net sales |
| Revenue | ¥8.7bn | 2023-12-01 → 2024-11-30 | Standalone | Net sales |
| Revenue | ¥8.4bn | 2022-12-01 → 2023-11-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥8.2bn | 2021-12-01 → 2022-11-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.7bn | 2020-12-01 → 2021-11-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥376m | 2024-12-01 → 2025-11-30 | Standalone | Operating income |
| Operating income | ¥362m | 2023-12-01 → 2024-11-30 | Standalone | Operating income |
| Ordinary income | ¥379m | 2024-12-01 → 2025-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥376m | 2023-12-01 → 2024-11-30 | Standalone | Ordinary income |
| Ordinary income | ¥333m | 2022-12-01 → 2023-11-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥262m | 2021-12-01 → 2022-11-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥329m | 2020-12-01 → 2021-11-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥378m | 2024-12-01 → 2025-11-30 | Standalone | Income before income taxes |
| Profit before tax | ¥418m | 2023-12-01 → 2024-11-30 | Standalone | Income before income taxes |
| Net income | ¥277m | 2024-12-01 → 2025-11-30 | Standalone | Profit loss |
| Net income | ¥324m | 2023-12-01 → 2024-11-30 | Standalone | Profit loss |
| Net income | ¥246m | 2022-12-01 → 2023-11-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥185m | 2021-12-01 → 2022-11-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥242m | 2020-12-01 → 2021-11-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.6bn | at 2025-11-30 | Standalone | Assets |
| Total assets | ¥8.3bn | at 2024-11-30 | Standalone | Assets |
| Total assets | ¥8.1bn | at 2023-11-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥8.2bn | at 2022-11-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.8bn | at 2021-11-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥5.7bn | at 2025-11-30 | Standalone | Liabilities |
| Total liabilities | ¥5.6bn | at 2024-11-30 | Standalone | Liabilities |
| Net assets / equity | ¥2.9bn | at 2025-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.7bn | at 2024-11-30 | Standalone | Net assets |
| Net assets / equity | ¥2.5bn | at 2023-11-30v | Standalone | Net assets |
| Net assets / equity | ¥2.2bn | at 2022-11-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.1bn | at 2021-11-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥968m | at 2025-11-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥506m | at 2024-11-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥227.22 | 2024-12-01 → 2025-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥265.81 | 2023-12-01 → 2024-11-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.87 | 2022-12-01 → 2023-11-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.85 | 2021-12-01 → 2022-11-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥198.64 | 2020-12-01 → 2021-11-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥60 | 2024-12-01 → 2025-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-12-01 → 2024-11-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2022-12-01 → 2023-11-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2021-12-01 → 2022-11-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥50 | 2020-12-01 → 2021-11-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,378.89 | at 2025-11-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,203.77 | at 2024-11-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,015.67 | at 2023-11-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,847.66 | at 2022-11-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,758.24 | at 2021-11-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 33.6% | at 2025-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-11-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.2% | at 2023-11-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2022-11-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.6% | at 2021-11-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.9% | 2024-12-01 → 2025-11-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.6% | 2023-12-01 → 2024-11-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.5% | 2022-12-01 → 2023-11-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-12-01 → 2022-11-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.9% | 2020-12-01 → 2021-11-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,220,000 | at 2025-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2024-11-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2023-11-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2022-11-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,220,000 | at 2021-11-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 155 | at 2025-11-30 | Standalone | Number of employees |
| Employees | 165 | at 2024-11-30 | Standalone | Number of employees |
| Employees | 160 | at 2023-11-30v | Standalone | Number of employees |
| Employees | 166 | at 2022-11-30v | Standalone | Number of employees |
| Employees | 159 | at 2021-11-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Pharmaceutical Productsreportable segment | capex | 2024-12-01 → 2025-11-30 | ¥698m |
| Pharmaceutical Productsreportable segment | depreciation | 2024-12-01 → 2025-11-30 | ¥427m |
| Pharmaceutical Productsreportable segment | employees | at 2025-11-30 | 159 pure |
| Pharmaceutical Productsreportable segment | revenue | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Pharmaceutical Productsreportable segment | revenue external | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Pharmaceutical Productsreportable segment | segment assets | at 2025-11-30 | ¥8.8bn |
| Pharmaceutical Productsreportable segment | segment profit | 2024-12-01 → 2025-11-30 | ¥396m |
| Real Estate Leasingreportable segment | employees | at 2025-11-30 | 1 pure |
| Real Estate Leasingreportable segment | revenue | 2024-12-01 → 2025-11-30 | ¥38m |
| Real Estate Leasingreportable segment | revenue external | 2024-12-01 → 2025-11-30 | ¥38m |
| Real Estate Leasingreportable segment | segment assets | at 2025-11-30 | ¥71m |
| Real Estate Leasingreportable segment | segment profit | 2024-12-01 → 2025-11-30 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-12-01 → 2025-11-30 | ¥698m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-12-01 → 2025-11-30 | ¥427m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-12-01 → 2025-11-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-12-01 → 2025-11-30 | ¥427m |
| Pharmaceutical Productsreportable segment | capex | 2023-12-01 → 2024-11-30 | ¥344m |
| Pharmaceutical Productsreportable segment | depreciation | 2023-12-01 → 2024-11-30 | ¥404m |
| Pharmaceutical Productsreportable segment | revenue | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Pharmaceutical Productsreportable segment | revenue external | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Pharmaceutical Productsreportable segment | segment assets | at 2024-11-30 | ¥8.5bn |
| Pharmaceutical Productsreportable segment | segment profit | 2023-12-01 → 2024-11-30 | ¥347m |
| Real Estate Leasingreportable segment | revenue | 2023-12-01 → 2024-11-30 | ¥38m |
| Real Estate Leasingreportable segment | revenue external | 2023-12-01 → 2024-11-30 | ¥38m |
| Real Estate Leasingreportable segment | segment assets | at 2024-11-30 | ¥71m |
| Real Estate Leasingreportable segment | segment profit | 2023-12-01 → 2024-11-30 | ¥31m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-12-01 → 2024-11-30 | ¥344m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-12-01 → 2024-11-30 | ¥404m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-12-01 → 2024-11-30 | ¥8.9bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-11-30 | ¥8.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-12-01 → 2024-11-30 | ¥378m |
| Pharmaceutical Productsreportable segment | employees | at 2025-11-30 | 154 pure |
| Real Estate Leasingreportable segment | employees | at 2025-11-30 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,479
| Item | Context | Value | Unit |
|---|---|---|---|
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000HommaYoshitakaMember | Original text (Japanese)取締役経理部長 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000HommaYoshitakaMember | Original text (Japanese)本間義隆 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000HommaYoshitakaMember | 1967-01-16 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E01006-000HommaYoshitakaMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000HommaYoshitakaMember | Original text (Japanese)(注)2 | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000MiyamotoHiroshiMember | Original text (Japanese)取締役(監査等委員) | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000MiyamotoHiroshiMember | Original text (Japanese)宮本浩士 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000MiyamotoHiroshiMember | 1961-11-30 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E01006-000MiyamotoHiroshiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000MiyamotoHiroshiMember | Original text (Japanese)(注)3 | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000IshigamiNaohiroMember | Original text (Japanese)取締役(監査等委員) | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000IshigamiNaohiroMember | Original text (Japanese)石上尚弘 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000IshigamiNaohiroMember | 1960-02-12 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E01006-000IshigamiNaohiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000IshigamiNaohiroMember | Original text (Japanese)(注)3 | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000SuzukiShunsukeMember | Original text (Japanese)取締役(監査等委員) | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000SuzukiShunsukeMember | Original text (Japanese)鈴木俊介 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000SuzukiShunsukeMember | 1969-03-07 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E01006-000SuzukiShunsukeMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E01006-000SuzukiShunsukeMember | Original text (Japanese)(注)3 | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | － | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)三菱ケミカルグループ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)化学工業薬品事業の取引を行っており、安定的な取引関係を強化・維持するため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)西川ゴム工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)化学工業薬品事業の取引を行っており、安定的な取引関係を強化・維持するため。株式数の増加は、株式分割によるものであります。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)三井化学㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)化学工業薬品事業の取引を行っており、安定的な取引関係を強化・維持するため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)住友理工㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)オカモト㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)化学工業薬品事業の取引を行っており、安定的な取引関係を強化・維持するため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱三菱ＵＦＪフィナンシャル・グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)議決権行使権限（退職給付信託） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)無 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |